Conjunctivoplasty — Cost, Top Hospitals & Success Rates | MyMedicPlus

Conjunctivoplasty refers to a group of surgical procedures designed to repair, reconstruct, or remodel the conjunctiva — the thin, transparent mucous membrane that covers the white of the eye (bulbar conjunctiva) and lines the inner surface of the eyelids (palpebral conjunctiva). The conjunctiva serves as an important protective barrier, produces mucin as part of the tear film, and hosts accessory lacrimal glands critical for ocular surface health.

The most common indication for conjunctivoplasty is pterygium excision with conjunctival autograft — removal of a pterygium (a wedge-shaped growth of fibrovascular tissue advancing from the conjunctiva onto the cornea) and reconstruction of the excised area with a graft of healthy conjunctiva from the superior bulbar conjunctiva of the same eye. Other indications include lysis and repair of symblepharon (adhesions between the bulbar and palpebral conjunctiva), fornix reconstruction in cicatricial ocular surface diseases (Stevens-Johnson syndrome, ocular cicatricial pemphigoid), pinguecula excision, tumour resection, and wound repair after trauma or chemical injury.

The procedure is performed under local anaesthesia with sedation (for outpatient cases) or general anaesthesia (for complex reconstruction in children or patients unable to cooperate), and typically takes 30–90 minutes depending on complexity. An operating microscope provides the magnification necessary for the delicate tissue manipulation involved. Modern conjunctivoplasty using fibrin glue for graft attachment has replaced suture fixation in many settings, reducing operative time and improving patient comfort.

Pterygium excision and conjunctival autograft (CLAG or CAG) is the most common conjunctivoplasty procedure. A pterygium is a benign proliferation of fibrovascular tissue that grows from the interpalpebral bulbar conjunctiva onto the cornea, most commonly on the nasal side. It causes redness, irritation, and — when it encroaches on the visual axis — progressive vision reduction from irregular corneal astigmatism. Surgical excision with autologous conjunctival grafting reduces recurrence rates to 5–10% compared to 30–80% with bare sclera excision alone.

Symblepharon is an adhesion between the bulbar conjunctiva (overlying the eyeball) and the palpebral conjunctiva (lining the eyelid), which restricts ocular motility, causes diplopia, distorts the tear film, and can prevent normal eyelid closure. Causes include chemical burns, thermal burns, Stevens-Johnson syndrome, ocular mucous membrane pemphigoid, and previous surgery. Conjunctivoplasty with mucous membrane grafting (from the oral mucosa, nasal septum, or amniotic membrane) reconstructs the fornix and separates the adhesions. Conjunctival tumour excision (for squamous cell carcinoma of the conjunctiva, limbal dermoids, naevi, and other lesions) with margin-controlled excision and conjunctival reconstruction is another important indication.

Patients with pterygium causing visual symptoms (reduced acuity, induced astigmatism), affecting the visual axis (approaching or crossing the pupil), producing significant cosmetic concern, or having reached 2–3 mm on the cornea are candidates for excision. Symptomatic pingueculae (raised yellow-white deposits on the bulbar conjunctiva without corneal invasion) causing persistent irritation, redness, or cosmetic concerns may also be candidates for excision.

Patients with symptomatic symblepharon limiting ocular motility, causing persistent corneal exposure, or threatening vision from corneal involvement are candidates for lysis and reconstruction. Patients with progressive cicatricial ocular surface diseases (Stevens-Johnson syndrome, pemphigoid) require specialised assessment at tertiary ocular surface disease centres before any conjunctivoplasty, as surgery in an active inflammatory phase can worsen outcomes. Children with congenital or acquired lid abnormalities causing conjunctival scarring may require conjunctivoplasty under general anaesthesia.

Pterygium excision with conjunctival autograft (CAG) is the gold standard surgical approach. After excising the pterygium under topical and subconjunctival local anaesthesia, a thin graft of healthy conjunctiva — taken from the superior bulbar conjunctiva of the same eye, preserving limbal stem cells in the limbal conjunctival autograft (CLAG) variant — is sutured or glued over the bare sclera defect. Fibrin glue attachment has largely replaced sutures in many centres, reducing operative time by 30 minutes and improving patient comfort in the post-operative period.

Amniotic membrane transplantation (AMT) uses preserved human amniotic membrane as a biological substitute for conjunctival reconstruction when autologous tissue is insufficient, scarred, or previously used. Amniotic membrane provides anti-inflammatory, anti-scarring, and stem-cell-supporting properties that enhance ocular surface healing. For fornix reconstruction after severe cicatricial disease, buccal mucosa grafts (harvested from the inside of the cheek) provide durable reconstruction of the fornix with good long-term outcomes. Mitomycin C (MMC) — an antifibrotic agent applied intraoperatively or post-operatively — reduces pterygium recurrence rates further (to 3–8%) when used as an adjunct to conjunctival autografting at high-risk cases.

Individualised treatment planning is essential to achieve optimal outcomes. Factors including patient age, overall health status, concurrent medications, and personal goals all influence the selection and sequencing of treatment approaches. A specialist consultation — with review of relevant investigations and prior treatment history — is the appropriate first step before any therapeutic intervention is initiated. Patients are encouraged to seek a second opinion for complex or elective procedures to ensure they understand all available options and their respective risks, benefits, and costs.

Pterygium excision with conjunctival autograft achieves recurrence rates of 5–10%, dramatically lower than the 30–80% rate with bare sclera excision. Corneal astigmatism induced by the pterygium typically improves significantly after excision — a benefit that may take 3–6 months to stabilise. Cosmetic improvement with elimination of the visible fibrovascular growth on the white of the eye is immediately apparent and provides significant psychological benefit.

For symblepharon release and fornix reconstruction, successful surgery restores ocular motility and tear distribution, reducing the risk of exposure keratopathy and corneal scarring. Quality-of-life improvements after effective conjunctivoplasty — reduction in chronic eye redness, irritation, watering, and visual disturbance — are consistently high in published outcome series. Amniotic membrane transplantation accelerates healing of acute ocular surface burns and chemical injuries, reducing long-term scarring and fornix obliteration when applied promptly.

Pterygium recurrence remains the most common complication, occurring in approximately 5–10% of CAG cases and 3–8% of CAG+MMC cases. Recurrent pterygium is more aggressive and more difficult to treat than primary pterygium. Risk factors for recurrence include young age at first excision, living in tropical or high UV-exposure environments, and not using UV-blocking sunglasses post-operatively.

Graft-related complications include graft dehiscence (slippage of the conjunctival graft), graft necrosis, and graft harvesting complications (buttonhole in the donor site, excessive reduction of the superior bulbar conjunctiva). Dellen (a localised area of stromal thinning adjacent to a raised graft edge) may occur post-operatively and usually responds to intensive lubricant drops. Ocular perforation from inadvertent scleral entry during aggressive pterygium dissection is a rare but serious complication. Mitomycin C, if used incorrectly, can cause scleral melt (progressive scleral thinning leading to perforation) — a serious late complication requiring careful MMC dose management.

After conjunctivoplasty, a shield or patch is applied for 24 hours. Topical antibiotic-steroid drops (e.g., dexamethasone with neomycin, or chloramphenicol with betamethasone) are prescribed 4 times daily for 4–6 weeks to prevent infection and graft rejection. Lubricant eye drops are used frequently throughout the day for 3–6 months to support ocular surface healing. Contact lens use and swimming are avoided for 4 weeks.

Follow-up appointments occur at 1 day (graft position check), 1 week, 4 weeks, and 3 months post-operatively. Sutures are removed at 1–2 weeks if non-absorbable sutures were used. The surgeon assesses graft integration, early recurrence signs, and visual acuity at each visit. Patients are counselled on the importance of UV-protecting wraparound sunglasses and lubricant use to minimise recurrence risk, particularly in patients with outdoor occupations or UV-exposed lifestyles.

Pterygium excision with conjunctival autograft in the United States costs USD 1,500–4,000 at outpatient surgical centres. In the UK, pterygium surgery is available on the NHS for symptomatic cases; private treatment costs GBP 800–2,500. Complex symblepharon release and fornix reconstruction involving amniotic membrane transplantation or oral mucosa grafting costs more due to longer operative time and the materials involved.

Medical tourism for conjunctivoplasty offers significant savings, particularly for elective pterygium surgery: at ophthalmology centres in India (Sankara Nethralaya, LV Prasad Eye Institute, Aravind Eye Care), the cost is USD 150–500 for pterygium excision with CAG including follow-up; in Thailand (Rutnin Eye Hospital, Bangkok) USD 300–700; in Turkey USD 200–500. These are world-class ophthalmic centres with internationally trained surgeons, performing high volumes of pterygium surgery. Medical tourists planning conjunctivoplasty abroad should allow 1–2 weeks for post-operative follow-up before travelling home.

Small asymptomatic pterygia not involving the visual axis can be managed with lubricant eye drops and UV protection to minimise symptoms and slow progression. Topical anti-inflammatory drops may reduce associated redness and irritation. However, once a pterygium reaches 2–3 mm on the cornea or begins to affect vision, surgery is the only definitive treatment — pharmacological approaches cannot remove existing fibrovascular tissue.

For symblepharon from acute chemical injury, immediate copious irrigation and insertion of a ring-shaped symblepharon ring (a smooth ring placed in the conjunctival fornix during healing) can prevent adhesion formation — an important preventive measure in the acute phase that is far preferable to surgical release months later. Amniotic membrane transplantation in the acute phase (within 2 weeks of injury) is the most effective intervention to prevent conjunctival scarring and fornix obliteration after severe chemical burns. Medical management of the underlying inflammatory disease (cicatricial pemphigoid, Stevens-Johnson) must precede any surgical intervention for cicatricial conjunctivoplasty.